Antiretroviral and Antituberculosis Therapy in HIV-TB Co-Infected Children

被引：0

作者：

Slogrove, Amy L. ^{[1
,2
,3
]}

Rabie, Helena ^{[1
,2
,4
]}

Cotton, Mark F. ^{[1
,2
,3
,4
]}

机构：

[1] Stellenbosch Univ, Fac Hlth Sci, Tygerberg Childrens Hosp, Cape Town, South Africa

[2] Stellenbosch Univ, Fac Hlth Sci, Dept Paediat & Child Hlth, Cape Town, South Africa

[3] Stellenbosch Univ, South South Partnership Comprehens Family HIV Car, Cape Town, South Africa

[4] Stellenbosch Univ, KID CRU Childrens Infect Dis Clin Res Unit, Cape Town, South Africa

来源：

CURRENT PEDIATRIC REVIEWS | 2011年 / 7卷 / 03期

关键词：

Antiretroviral therapy; antituberculosis therapy; TB-HIV co-infection; children;

D O I：

10.2174/157339611796548474

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

HIV-infected children experience a high burden of tuberculosis. With recent advances in international pediatric HIV treatment guidelines significant numbers of infants and children will require simultaneous treatment for both TB and HIV. This article attempts to concisely outline strategies for effective co-treatment of both infections. Rifamycins, an essential component of short course TB chemotherapy, alter the metabolism of a number of antiretroviral drugs. These interactions and their consequences are considered. Options for antiretroviral therapy and the optimal timing of its initiation in the presence of antituberculosis therapy are discussed.

引用

页码：173 / 179

页数：7

共 66 条

[1]

Al-Dabbagh M, 2011, PIDJ, V30

[2] Drug metabolism and disposition in children [J].

Benedetti, MS ;

Baltes, EL .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (03) :281-299

[3]

Blanc FX, 2010, SIGNIFICANT ENHANCEM

[4]

Bong CN, 2007, INT J TUBERC LUNG D, V11, P534

[5] Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy [J].

Boulle, Andrew ;

Van Cutsem, Gilles ;

Cohen, Karen ;

Hilderbrand, Katherine ;

Mathee, Shaheed ;

Abrahams, Musaed ;

Goemaere, Eric ;

Coetzee, David ;

Maartens, Gary .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (05) :530-539

[6] Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens [J].

Burman, William J. ;

Cotton, Mark F. ;

Gibb, Diana M. ;

Walker, A. Sarah ;

Vernon, Andrew A. ;

Donald, Peter R. .

PLOS MEDICINE, 2008, 5 (08) :1168-1172

[7] Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials [J].

Burman, WJ ;

Gallicano, K ;

Peloquin, C .

CLINICAL PHARMACOKINETICS, 2001, 40 (05) :327-341

[8]

Chadwick EG, 2005, PEDIATR INFECT DIS J, V24, P793, DOI [10.1097/01.inf.0000111281.93658.df, 10.1097/01.inf.0000177281.93658.df]

[9] Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid [J].

Cilliers, K. ;

Labadarios, D. ;

Schaaf, H. S. ;

Willemse, M. ;

Maritz, J. S. ;

Werely, C. J. ;

Hussey, G. ;

Donald, P. R. .

ACTA PAEDIATRICA, 2010, 99 (05) :705-710

[10]

Davies G, 2007, COCHRANE DB SYST REV, V17

← 1 2 3 4 5 6 7 →